Next-Generation Immunology Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Next-Generation Immunology Drugs Market is segmented by Drug Class (Small Molecules, Antibodies, Cell-Based Therapies, Others), Therapeutic Area (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Others), Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The report offers the value in USD million for the above segments.

Next-Generation Immunology Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Next-Generation Immunology Drugs Industry Overview

The next-generation immunology drugs market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The market players are focusing on new product launches, R&D, and expansions to gain a competitive advantage. Some of the market's major players include AbbVie Inc., Amgen Inc., AstraZeneca, GlaxoSmithKline PLC, Novartis AG, and F. Hoffmann-La Roche AG.

Next-Generation Immunology Drugs Market Leaders

  1. AbbVie

  2. Novartis AG

  3. GSK plc

  4. Pfizer Inc.

  5. Bristol-Myers Squibb Company

  6. *Disclaimer: Major Players sorted in no particular order
Next Generation Immunology Drugs Market Concentration

Next-Generation Immunology Drugs Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?